Core Viewpoint - The article emphasizes the importance of scientific weight management, which should focus on reducing excess body fat while maintaining or even increasing muscle mass to protect overall health [5][7]. Group 1: Weight Management "Three Must-Dos" - First, strictly control energy intake by limiting high-energy density foods, particularly those high in sugar and fats [9][10]. - Second, increase the consumption of foods that are low in calories but high in satiety, such as green and dark vegetables, whole grains, and soy products [11]. - Third, for individuals who are solely overweight and prefer staple foods, it is recommended to gradually reduce the amount of staple foods consumed, ideally by half a liang (approximately 25 grams) per week [13]. Group 2: Weight Management "Four Avoidances" - First, avoid eating too quickly; meals should last at least 20 minutes to prevent excessive energy intake [15]. - Second, avoid overeating by developing a habit of eating until 70-80% full [16]. - Third, avoid late-night meals, as they can disrupt the body's biological clock and increase the risk of obesity [17]. - Fourth, avoid excessive snacking or casual eating, as these can contribute significantly to total daily energy intake [18]. Group 3: Weight Management "One Adjustment" - One adjustment is to scientifically arrange the order of meals, starting with low-energy but high-satiety foods before consuming higher-energy foods, which can help reduce overall food and energy intake [19]. Group 4: National Strategy - The National Health Commission of China has initiated a three-year "Weight Management Year" action plan, aiming to significantly enhance public awareness and skills in weight management by 2026, with a target of reducing the annual obesity rate increase by 10% [27].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 你有没有注意到，冬天似乎更容易变瘦，而到了夏天体重却容易增加？其实，这种现象并非你的错觉！近期，丹麦哥本哈根大学联合瑞典卡罗 林斯卡学院的研究团队发现，季节性的光照时长变化会通过调控进食规律，从而影响人体的能量代谢与脂肪储存。 这项刊登在《Cell Metabolism》的最新成果，让我们看到了无需节食或锻炼也能瘦身的"天然减重新思路"。 一、光照如何成为"隐形减脂教练" 短日照：激活身体的"燃脂开关" 在实验中，科学家们将小鼠分为三组，分别模拟夏季（18小时光照）、冬季（6小时光照）和赤道（12小时光照）的环境。经过13周观察，发 现冬季短日照组（SL）的小鼠体重和脂肪量明显低于另外两组，尤其是高脂饮食的小鼠，脂肪堆积减少最为显著，肝脏中的甘油三酯含量也 下降了约20%。 更令人惊喜的是，短日照组小鼠的能量消耗（EE）呈上升趋势（p=0.061）。这就像身 ...

Core Viewpoint - The article discusses the approval and potential of TQF3250, an oral GLP-1 receptor agonist developed by China National Pharmaceutical Group, for weight management and type 2 diabetes treatment, highlighting the growing global obesity crisis and the need for effective treatments [6][8]. Group 1: TQF3250 Development and Approval - TQF3250 has received FDA approval for clinical trials aimed at weight management and has also been accepted for trials in type 2 diabetes treatment by the NMPA in China [6]. - The drug is designed to selectively activate the cAMP-dependent GLP-1 receptor signaling pathway, promoting insulin secretion while minimizing gastrointestinal side effects, thus offering a differentiated advantage over existing injectable GLP-1 products [8]. Group 2: Global Obesity Trends - The global prevalence of overweight and obesity is projected to rise from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people [6]. - In China, it is estimated that by 2025, 41% of adults will have a BMI ≥ 25 kg/m², with 9% classified as obese, leading to a projected 515 million adults with high BMI by 2030 [6]. Group 3: Health Implications of Obesity - In 2021, approximately 16 million premature deaths among adults were attributed to obesity-related diseases, with chronic non-communicable diseases accounting for 27% of the global disease burden [6]. - About 55% of premature deaths from type 2 diabetes are closely linked to obesity, indicating a significant gap in the supply of effective obesity management and treatment options [6].

整理 | GLP1减重宝典内容团队 加州大学圣迭戈分校的睡眠研究者Atul Malhotra表示，GLP-1类药物的作用不仅限于减重，可能还涉及代谢、炎症甚至神经调节机制。 肥胖是OSA最重要的可控风险因素之一，减重常带来明显改善。NYU Langone睡眠中心的Alcibiades Rodriguez表示："我们经常看到患 者通过传统方式、代谢手术或GLP-1类药物减重后，睡眠呼吸暂停得到改善，甚至完全缓解。"早期，他主要在为糖尿病或减重开具 GLP-1药物的患者中观察到这些改善，如今该药已获批用于OSA，他也将其纳入常规治疗。"一些患者减重后从每晚依赖CPAP，变成几 乎不再需要使用。"研究也在揭示这些药物对睡眠的积极影响可能超越体重因素，为管理代谢、心肺和睡眠健康提供更多思路。 点击关注，追踪最新GLP-1资讯 替尔泊肽获批用于OSA是一个里程碑。这是首个被允许用于睡眠呼吸暂停的GLP-1药物，也是首个专门用于OSA治疗的FDA批准药物。 此前，OSA主要依靠CPAP等机械手段或外科干预。该批准基于SURMOUNT-OSA研究，结果显示在肥胖人群中，替尔泊肽可显著降低 AHI评分，并推动部分患者从重度转 ...

Core Viewpoint - The article discusses the potential of GLP-1 medications, particularly tirzepatide and semaglutide, in reducing food cravings and improving mental health in individuals with obesity and eating disorders, highlighting recent research findings and real-world survey results [4][8][10]. Group 1: Research Findings on Tirzepatide - A study monitoring brain activity in a patient with severe binge eating disorder found that tirzepatide temporarily suppressed food craving signals in the brain's reward center [4]. - The research involved four participants in a clinical trial for deep brain stimulation aimed at treating eating disorders, with one patient showing reduced food-related intrusive thoughts while on tirzepatide [4]. - However, after five months, the effects of tirzepatide diminished, and food cravings returned, suggesting that current GLP-1 drugs may need redesigning to target brain reward mechanisms for sustained impact on eating disorders [6]. Group 2: Real-World Impact of Semaglutide - The INFORM survey presented at the EASD conference revealed that 46% of participants using semaglutide reported a significant reduction in persistent food thoughts, with the percentage of those frequently experiencing such thoughts dropping from 62% to 16% [8][11]. - Additionally, the negative impact of food noise on life quality decreased from 60% to 20% among respondents, indicating a substantial improvement in mental health and lifestyle changes [11]. - Overall, 83% of participants expressed satisfaction with semaglutide treatment, with 64% reporting improved mental health and 76% adopting healthier lifestyles [11][12]. Group 3: Understanding Food Noise - Food noise refers to intrusive thoughts about food that are not related to hunger and can significantly affect the quality of life for individuals with obesity, complicating their weight loss efforts [10][14]. - This phenomenon is common among obese patients and can lead to feelings of guilt, shame, and anxiety, further hindering weight loss progress [14].

Core Viewpoint - The article discusses the recent developments in GLP-1/GIP dual receptor agonist RAY1225, highlighting its clinical research approval for treating metabolic-associated fatty liver disease (MASH) and its potential in weight management and diabetes treatment [5][6]. Group 1: Product Development - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has received implied approval for RAY1225, a long-acting GLP-1/GIP dual receptor agonist, for clinical research in MASH [5]. - RAY1225 is an innovative polypeptide drug developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., which has previously obtained clinical research approval for indications related to type 2 diabetes and overweight/obesity [5]. Group 2: Clinical Trials - The company announced results from the Phase II clinical trial (REBUILDING-1) for weight management, which included 172 participants who were either overweight or obese [6]. - Participants received RAY1225 (3 mg, 6 mg, 9 mg) or a placebo, with injections administered every two weeks over a 24-week treatment period [6]. - The dosing regimen included a gradual titration to target doses, with total administered doses of 30 mg for the 3 mg group, 50 mg for the 6 mg group, and 68 mg for the 9 mg group [6].

Core Viewpoint - The article discusses a recent study published in *Nature Communications* that challenges the effectiveness of exercise as a weight loss strategy, particularly in the context of high-fat diets, highlighting potential negative impacts on heart health and lipid metabolism [6][7][11]. Group 1: Study Overview - The research involved dividing mice into normal diet (10% fat) and high-fat diet (60% fat) groups, further categorized into sedentary and various exercise intensity groups (low, medium, high) over an 8-week period [8]. - Mice in the exercise groups ran on a treadmill for 60 minutes, five days a week, at speeds of 6, 12, and 18 meters per minute [8]. Group 2: Effects of Exercise on Heart Health - Moderate-intensity exercise was found to exacerbate heart function impairment and pathological changes caused by high-fat diets, including decreased cardiac diastolic and systolic function, increased heart hypertrophy, and fibrosis [9]. - High-fat diet sedentary mice showed decreased exercise performance, and moderate-intensity exercise further reduced performance in high-fat diet mice, while normal diet mice showed little change [9]. Group 3: Lipid Metabolism Insights - Moderate-intensity exercise increased lipid accumulation in the hearts of high-fat diet mice, with elevated levels of triglycerides, diacylglycerols, ceramides, and cholesterol [10]. - The study indicated that moderate-intensity exercise led to a redistribution of circulating lipids from the liver and adipose tissue to the heart, increasing the presence of labeled fatty acids in the heart [10]. - Gene and protein expression analyses revealed that moderate-intensity exercise enhanced the expression of genes related to fatty acid uptake while reducing those related to fatty acid breakdown, leading to increased lipid accumulation and impaired heart function [10]. Group 4: Conclusion and Recommendations - The findings suggest that relying solely on exercise after high-fat meals may not be effective for weight management and could harm heart health [11]. - A balanced approach combining appropriate dietary choices with suitable exercise regimens is recommended for healthy weight loss [11].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 肥胖已非个体困扰，实为国家层面的公共卫生紧急状态。"体重管理年"旨在通过政策引导与社会协同，遏制体重飙升势头。新《指导原则》不 仅普及科学减重，更推动健康餐饮、运动设施及医疗服务的系统升级。数据显示，2021年中国25岁以上超重肥胖人口已达4.02亿，若无干预， 2050年将猛增至6.27亿，儿童肥胖也将达3520万。这意味着未来数代人健康负担沉重，医疗体系承压，国民经济受创。出台指南，是国家为全 民健康"抢时间"，为社会未来"卸包袱"。 这场危机有其深因。高糖高脂外卖泛滥、久坐办公普遍、运动资源短缺，叠加快节奏压力与睡眠不足，肥胖率如雪崩般增长。国家认识到，仅 凭个人难以抵御环境诱惑，必须通过政策优化饮食结构、提升运动便利、推广"控重门诊"，使减重从单打独斗转为社会工程。目标清晰：让健 康更可及，逆转这场"肥胖危机"！ 曾被视为"瘦国"的中国，如今已成全球超重人口大国。《柳叶刀》研究指出，2021年全球超重肥胖者26亿，中国占超4亿，位列前茅。更甚 ...

Core Viewpoint - The World Health Organization (WHO) has officially integrated GLP-1 receptor agonists into long-term obesity management guidelines, emphasizing the need for behavioral interventions alongside pharmacological treatments, marking a shift in the perception of GLP-1 from an "innovative drug" to a "structural treatment tool" for chronic disease management [4][5]. Background and Context - Obesity is recognized as a critical public health challenge, affecting over one billion people globally, with related diseases increasingly contributing to non-communicable disease burdens [5]. - The new guidelines highlight the persistent and relapsing nature of obesity, necessitating comprehensive management strategies, with GLP-1 drugs demonstrating significant efficacy in weight management and metabolic health improvement in large clinical studies [5]. Long-term Management Approach - The guidelines assert that obesity requires lifelong management, encompassing screening, early diagnosis, and complication management, potentially integrating pharmacological treatments, metabolic surgery, or other interventions [7]. - Patients should receive lifestyle-related counseling, including increased physical activity and dietary improvements, especially those using GLP-1 receptor agonists [7][8]. Expert Insights - WHO officials acknowledge that while new obesity treatment drugs represent a breakthrough, they cannot singularly resolve the obesity crisis, which is driven by multiple factors and requires long-term management and collaboration across healthcare systems, public policies, and social environments [9][10]. Clinical Expansion and Market Growth - The use of GLP-1 drugs is rapidly expanding, with prescription rates increasing significantly in recent years, reflecting both patient recognition of efficacy and a shift in physician attitudes towards long-term management [12]. - Pharmaceutical companies like Eli Lilly and Novo Nordisk have reported substantial growth in their financial results, with GLP-1 products becoming core drivers of their business [12]. Global Accessibility Concerns - High drug prices pose a barrier to the inclusion of GLP-1 in routine treatment in many low- and middle-income countries, with supply shortages exacerbating the issue [13]. - International public health organizations are exploring centralized procurement and differential pricing mechanisms to address inequalities in obesity management access [13][15]. Future Directions and Challenges - The competition in the weight loss drug market is intensifying, with leading pharmaceutical companies investing in production expansion and new entrants seeking technological breakthroughs [17]. - The future landscape of GLP-1 drugs will be shaped by innovations in mechanisms, dosage forms, and cost structures, with the potential for generic drugs to enhance global accessibility [15][17]. - Policymaking will significantly influence market dynamics, including decisions on insurance coverage and payment mechanisms, which will directly affect patient costs and healthcare resource allocation [15][17].

Core Viewpoint - The article discusses the recent advancements in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) using semaglutide, highlighting its FDA approval and the positive outcomes from clinical trials [6][7][9]. Group 1: Clinical Guidelines and Recommendations - The latest practice guidelines published in *HEPATOLOGY* focus on the application of semaglutide in treating MASH, particularly for patients with moderate to advanced fibrosis (F2-F3 stages) [6]. - The guidelines integrate recent trial data, including the ESSENCE study, and provide actionable recommendations for clinical teams [6][9]. - Experts emphasize the rapid advancement in MASH research and the need for evidence-based treatment options to ensure patient safety and efficacy monitoring [6][9]. Group 2: FDA Approvals and Market Position - In June, Novo Nordisk announced that the FDA granted accelerated approval for its weight loss drug Wegovy for treating MASH, solidifying its position in the metabolic disease sector [6]. - Prior to this, the only FDA-approved MASH treatment was Madrigal Pharmaceuticals' Rezdiffra, which received approval in 2024 based on early results from an ongoing two-phase study [7]. Group 3: Clinical Trial Results - The ESSENCE study's first major endpoint showed that 62.9% of patients treated with 2.4 mg of semaglutide experienced resolution of steatohepatitis without worsening fibrosis, compared to 34.3% in the placebo group, indicating a significant difference of 28.7% [8]. - For the second major endpoint, 36.8% of the semaglutide group showed improvement in fibrosis without worsening steatosis, versus 22.4% in the placebo group, with a difference of 14.4% [8]. - The study's secondary endpoint revealed that 32.7% of patients on semaglutide had symptom relief and improved fibrosis, compared to only 16.1% in the placebo group, demonstrating a significant therapeutic effect [8]. Group 4: Implications for Clinical Practice - The updated guidelines reflect the evolving landscape of scientific progress and clinical practice, providing physicians with tools to manage MASH and MASLD more effectively [9]. - The emergence of therapies like semaglutide offers patients and healthcare providers more options for improving liver health and overall well-being [9].